Vertex Pharmaceuticals Incorporated Stock Annual Yield
VX1 Stock | EUR 383.00 2.70 0.71% |
Vertex Pharmaceuticals Incorporated fundamentals help investors to digest information that contributes to Vertex Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Vertex Stock. The fundamental analysis module provides a way to measure Vertex Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vertex Pharmaceuticals stock.
Vertex |
Vertex Pharmaceuticals Incorporated Company Annual Yield Analysis
Vertex Pharmaceuticals' Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.
Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.
Competition |
In accordance with the recently published financial statements, Vertex Pharmaceuticals Incorporated has an Annual Yield of 0.0%. This indicator is about the same for the Healthcare average (which is currently at 0.0) sector and about the same as Biotechnology (which currently averages 0.0) industry. This indicator is about the same for all Germany stocks average (which is currently at 0.0).
Vertex Annual Yield Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vertex Pharmaceuticals' direct or indirect competition against its Annual Yield to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vertex Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Vertex Pharmaceuticals by comparing valuation metrics of similar companies.Vertex Pharmaceuticals is currently under evaluation in annual yield category among its peers.
Vertex Fundamentals
Return On Equity | 0.28 | |||
Return On Asset | 0.17 | |||
Profit Margin | 0.37 % | |||
Operating Margin | 0.49 % | |||
Current Valuation | 67.44 B | |||
Shares Outstanding | 257.09 M | |||
Shares Owned By Insiders | 0.21 % | |||
Shares Owned By Institutions | 96.26 % | |||
Price To Earning | 18.50 X | |||
Price To Book | 6.23 X | |||
Price To Sales | 8.51 X | |||
Revenue | 8.93 B | |||
Gross Profit | 5.32 B | |||
EBITDA | 4.44 B | |||
Net Income | 3.32 B | |||
Cash And Equivalents | 3.95 B | |||
Cash Per Share | 15.37 X | |||
Total Debt | 656.95 M | |||
Debt To Equity | 12.90 % | |||
Current Ratio | 3.74 X | |||
Book Value Per Share | 54.13 X | |||
Cash Flow From Operations | 4.13 B | |||
Earnings Per Share | 11.89 X | |||
Price To Earnings To Growth | 0.42 X | |||
Target Price | 258.59 | |||
Number Of Employees | 4.8 K | |||
Beta | 0.46 | |||
Market Capitalization | 70.82 B | |||
Total Asset | 18.15 B | |||
Z Score | 64.2 | |||
Net Asset | 18.15 B |
About Vertex Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vertex Pharmaceuticals Incorporated's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vertex Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vertex Pharmaceuticals Incorporated based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Vertex Stock
Vertex Pharmaceuticals financial ratios help investors to determine whether Vertex Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Vertex with respect to the benefits of owning Vertex Pharmaceuticals security.